Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101

For full description, see www.clinicaltrials.gov.

Manuscripts/Articles:

• E. Gabriela Chiorean, Rashmi Ramasubbaiah, Menggang Yu, Joel Picus, Jose A. Bufill, Yan Tong, Nicki Coleman, Erica L. Johnston, Colleen Currie, Patrick J. Loehrer. Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101 Oncologist. 2012 January; 17(1): 13. doi: 10.1634/ theoncologist.2011-0253 PMCID: PMC3267812. See abstract.